Published in Vaccine Weekly, August 11th, 2004
The production capacity in this facility will initially be used to support the commercialization of StaphVAX (Staphylococcus aureus Polysaccharide Conjugate Vaccine), the company's lead product candidate initially targeted to prevent staph infections in end-stage renal (kidney) disease (ESRD) patients.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly